tulisokibart

News

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

Digital

Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.

Sales & Marketing

The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.